Osaka, Japan & Cambridge, Massachusetts, United States, June 24, 2026 — Takeda has officially appointed Julie Kim as Representative Director, President & Chief Executive Officer, completing the company’s planned 18-month CEO succession process. The appointment follows shareholder approval during Takeda’s 150th Annual General Meeting of Shareholders, after which the Board of Directors appointed Julie as Representative Director, President & CEO. She succeeds Christophe Weber, who retired from both the company and the Board following more than 12 years of leadership.
Julie Kim brings more than three decades of global healthcare experience and an established track record of driving innovation, expanding patient access to life-changing medicines, and delivering sustainable business growth. She joined Takeda in 2019 through the acquisition of Shire and has since held several senior executive leadership positions. Most recently, she served as CEO-elect, working closely with Christophe Weber and the Board during the planned leadership transition to ensure continuity and strategic alignment.
Prior to becoming CEO-elect, Julie led Takeda’s Plasma-Derived Therapies Business Unit as President, overseeing one of the company’s largest global businesses focused on delivering critical therapies for patients with rare and complex diseases. Earlier, she served as President of Takeda’s U.S. Business Unit, where she led commercial operations across one of the company’s largest markets, helping strengthen market performance while advancing patient-focused healthcare solutions. Throughout her tenure, she has played an instrumental role in shaping Takeda’s long-term growth strategy and reinforcing its position as a leading global biopharmaceutical company.
As President and Chief Executive Officer, Julie will lead Takeda into its next phase of growth, with the company preparing for three major product launches over the next 12 months while advancing a pipeline of five additional late-stage innovative assets. Under her leadership, Takeda will continue executing its long-term growth roadmap, focused on innovation, operational excellence, and delivering meaningful impact for patients, employees, shareholders, and healthcare systems worldwide.
Alongside Julie’s appointment, shareholders also elected Bruce Broussard, Koichiro Kimura, and Dr. Paul Stoffels as new external directors, further strengthening the Board’s governance and industry expertise. Following the Annual General Meeting, Takeda confirmed updated Board, Audit and Supervisory Committee, Nomination Committee, and Compensation Committee assignments, with external directors continuing to play a significant role in maintaining transparency, independence, and effective corporate governance.
About Takeda
Takeda is a leading values-based, research and development-driven global biopharmaceutical company headquartered in Japan. The company is focused on discovering and delivering life-transforming treatments across its core therapeutic areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
Operating in approximately 80 countries and regions, Takeda combines scientific innovation with a strong commitment to patients, its people, and the planet. Guided by more than two centuries of history, the company continues to advance a diverse pipeline of innovative medicines while working with partners around the world to improve patient outcomes and expand access to healthcare.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
